IL6 and cancer: Several immune-related pathways and events, including interferon (IFN) gamma/alpha response, IL-6–JAK-STAT3 signaling, allograft rejection, and inflammatory response, were upregulated in the low-risk group, while in the high-risk group, metabolic and cancer-promoting pathways, such as oxidative phosphorylation, glycolysis, MYC signaling, E2F signaling, and MTORC1 signaling, were activated (Figure 5A).